Backed by Italy-based Fondazione Telethon ETS, Waskyra, for Wiskott-Aldrich syndrome, is the first gene therapy from a ...
Fondazione Telethon ETS' Waskyra has become the first gene therapy in the US for patients with Wiskott-Aldrich syndrome (WAS) ...
The FDA has issued its stamp of approval to a new, cell-based option to treat Wiskott-Aldrich syndrome (WAS), marking the ...
The FDA on Tuesday approved etuvetidigene autotemcel (Waskyra) as the first cell-based gene therapy for patients 6 months and ...
The Food and Drug Administration this week granted approval to a new gene therapy for a rare immune disorder, the maker of which is notably not a drug ...
MedPage Today on MSN
Gene Therapy Maintains Efficacy in Hemophilia B Out to 5 Years
Based on initial positive results from HOPE-B, etranacogene dezaparvovec became the first gene therapy approved for adults ...
The first-of-its kind gene therapy uses a patient’s skin cells to create sheets to treat the open wounds caused by the rare, ...
Aradigm Health, a new benefits platform aimed at easing the financial sting of coverage for cell and gene therapies, has ...
The rate of severe infections decreased from 2 infections to 0.2 infections per PYO after treatment with etuvetidigene autotemcel.
Investment from XGEN Venture, British Business Bank, and a global biopharmaceutical company will support first-in-human Phase ...
Fondazione Telethon announced that FDA has approved its Biologics License Application (BLA) for Waskyra (etuvetidigene ...
A pioneering genetic treatment is saving lives where chemotherapy failed, offering new hope for children and adults with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback